In a Q&A with ILCN, Dr. Melissa Johnson recaps the trial’s positive results—and surprises—and discusses the potential roles sotorasib and other drugs in its class may play in treating KRAS G12C+ NSCLC. Read more
Tobacco Smoking-Related Mutational Signatures: Is it Time to Move on From Patient-Reported History?
+more
Study highlights limitations of relying solely on clinical smoking history, and findings suggest tobacco smoking-related mutational signatures could potentially guide molecular testing and optimize patient stratification in clinical trials. Read more
Conference chairs Drs. Paul Bunn, Charu Aggarwal, Lecia Sequist, and Joel Neal discuss what makes this meeting unique and share program highlights in a recent Q&A with ILCN. Read more
Studies that don’t show survival benefit with more frequent surveillance won’t convince patients they’re better off without scans. Even if regularly scheduled scans don’t help patients live longer, they do help them live better. Read more
IASLC is now accepting abstract submissions for WCLC 2023 and nominations for committee membership and leadership. Read more
Analyses by Drs. Matthew P. Smeltzer and Raymond U. Osarogiagbon show nodule and LDCT lung cancer screening programs may be serving two distinct populations with only moderate overlap. Read more
LALCA participants recap how the field of liquid biopsy continues to grow—from new biomarkers to new frontiers in early cancer detection. Read more
During the Closing Ceremony, five early-career, trainee, or resident investigators were honored for presenting at LALCA 2023. Read more
Patient Advocates Committee Chair Jill Feldman said ensuring the patient voice is present in research helps to improve the work being done to reduce the burden of lung cancer worldwide. Read more
Dr. Carolyn Dresler Joins Action on Smoking and Health (ASH) Board of Trustees; Novel Liquid Biopsy Assay for Lung Carcinoma Detection Receives FDA Breakthrough Device Designation. Read more